Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|15|3|284-304

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.15, Iss.3, 2008-02, pp. : 284-304

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Risk-Benefit Assessment of Pharmacotherapies for Clinical Depression in Children and Adolescents

By Renaud J.   Axelson D.   Birmaher B.  

Drug Safety, Vol. 20, Iss. 1, 1999-01 ,pp. : 59-75

Adis International

Access to resources Recommend Favorite

REM sleep and its Loss-Associated Epigenetic Regulation with Reference to Noradrenaline in Particular

By  

Current Neuropharmacology, Vol. 14, Iss. 1, 2016-01 ,pp. : 28-40

Bentham Science Publishers

Access to resources Recommend Favorite

Application of Bone Marrow Stem Cell Based Therapy in Bone Loss Diseases

By  

Current Pharmaceutical Design, Vol. 23, Iss. 41, 2018-02 ,pp. : 6288-6297

Bentham Science Publishers

Access to resources Recommend Favorite

Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus

By Horizon Arash A   Wallace Daniel J  

Expert Opinion on Drug Safety, Vol. 3, Iss. 4, 2004-07 ,pp. : 273-278

Informa Healthcare

Access to resources Recommend Favorite

Phenytoin associated with bone loss in young women

By  

Reactions Weekly, Vol. 1, Iss. 1200, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite